BioMarin Wins FDA Approval of Drug

BioMarin Pharmaceutical Inc. said the Food and Drug Administration approved marketing of a therapy against a rare fatal genetic disorder.

The company expects to receive the European Commission’s opinion on the treatment, known as Naglazyme, in the fourth quarter, Novato, Calif.-based BioMarin said. If the opinion is positive, final approval from the European regulator is expected in early 2006, it said.